3,100 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by North Dakota State Investment Board

Key Points

• North Dakota State Investment Board opened a new position in IDEXX Laboratories, buying 3,100 shares valued at about $2.1 million in the fourth quarter.
• Institutional ownership remains very high, with 87.84% of IDEXX shares held by institutions; several large investors also increased their stakes recently.
• IDEXX beat quarterly expectations, reporting EPS of $3.47 on $1.14 billion in revenue, while analysts currently rate the stock Moderate Buy with a consensus target price of $751.

North Dakota State Investment Board purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 3,100 shares of the company's stock, valued at approximately $2,097,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. grew its position in IDEXX Laboratories by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company's stock worth $6,364,638,000 after acquiring an additional 86,040 shares during the last quarter. Elyxium Wealth LLC bought a new position in IDEXX Laboratories during the 4th quarter worth approximately $3,666,459,000. Bank of New York Mellon Corp grew its position in IDEXX Laboratories by 41.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company's stock worth $1,313,992,000 after acquiring an additional 605,290 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in IDEXX Laboratories by 63,503.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company's stock worth $977,210,000 after acquiring an additional 1,442,174 shares during the last quarter. Finally, Invesco Ltd. grew its position in IDEXX Laboratories by 14.0% during the 3rd quarter. Invesco Ltd. now owns 1,320,263 shares of the company's stock worth $843,503,000 after acquiring an additional 161,782 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Barclays dropped their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a report on Thursday, February 5th. Citigroup assumed coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a "neutral" rating and a $650.00 price objective for the company. BTIG Research dropped their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a report on Tuesday, February 3rd. Weiss Ratings cut IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a report on Monday, May 11th. Finally, Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating for the company in a report on Tuesday, March 31st. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $751.00.

Insider Buying and Selling

In other news, EVP Nimrata Hunt sold 2,693 shares of the firm's stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the completion of the transaction, the executive vice president owned 19,899 shares in the company, valued at $13,163,984.46. This trade represents a 11.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm's stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the transaction, the chief executive officer owned 83,606 shares of the company's stock, valued at approximately $54,975,125.30. The trade was a 21.81% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 27,777 shares of company stock valued at $18,235,113. 0.79% of the stock is currently owned by company insiders.

IDEXX Laboratories Trading Up 3.2%

NASDAQ IDXX opened at $545.79 on Tuesday. IDEXX Laboratories, Inc. has a fifty-two week low of $496.61 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a 50 day simple moving average of $570.62 and a two-hundred day simple moving average of $644.92. The stock has a market cap of $43.05 billion, a P/E ratio of 40.19, a price-to-earnings-growth ratio of 3.07 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts' consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts' expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm's revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.